Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs.
CAS 9005-66-7
Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs. (CAS 9005-66-7) is a pharmaceutical compound with 0 bioactivity targets and 100 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs. is linked to DTXSID70897060 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs. used for in pharmaceutical contexts?
Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs. (CAS 9005-66-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs.?
Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs. has 100 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Balance disorder, Bladder disorder, Blood calcium decreased, Cognitive disorder, Constipation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs. also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Polysorbate 40 with EU status "permitted".
What clinical phase is Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs. in?
No phase 1-4 clinical development badge is rendered for Sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl) derivs. because the matched compound identifier rows do not contain a max-phase value.